Journal of Clinical Virology
Volume 46, Supplement 4 , Pages S68-S72, December 2009

Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases

  • Jie Zhong
    • ,
  • Rajiv Khanna

      Affiliations

    • Corresponding Author InformationCorresponding author at: Division of Infectious Diseases and Immunology, CBCRC Building, Queensland Institute of Medical Research, 300 Herston Rd, Brisbane 4029, Australia. Tel.: +61 7 3362 0385; fax: +61 7 3845 3510.

Australian Centre for Vaccine Development, Tumour Immunology Laboratory, Division of Immunology, Queensland Institute of Medical Research, Brisbane, Australia

Received 24 March 2009; received in revised form 2 July 2009; accepted 2 July 2009. published online 31 July 2009.

Abstract 

In spite of numerous attempts at successful licensure, a human cytomegalovirus (HCMV) vaccine formulation remains elusive. To overcome the limitations of previous strategies, we have recently developed a novel chimeric vaccine which allows induction of both humoral and cellular immune response following a single vaccination. This vaccine includes the extracellular domain of HCMV-encoded glycoprotein-B (gB) covalently linked to multiple HLA class I- and class II-restricted T-cell epitopes from multiple HCMV antigens as a contiguous polypeptide in a replication-deficient adenoviral vector Ad5/F35 (referred to as Ad-gBCMVpoly). Immunisation with Ad-gBCMVpoly consistently generated strong gB-specific neutralizing antibody and a broad range of HCMV-specific pluripotent CD8+ and CD4+ T-cells. This immunity suppressed infection with recombinant vaccinia virus encoding HCMV antigens. Furthermore, in vitro stimulation with Ad-gBCMVpoly rapidly expanded multiple antigen-specific human CD8+ and CD4+ T-cells from healthy virus carriers. Here we discuss the advantages of the Ad-gBCMVpoly vaccine and its potential application in different clinical settings.

Keywords: Virus, Vaccine, T cells, Antibody, Protection, Immunotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1386-6532(09)00325-4

doi:10.1016/j.jcv.2009.07.003

Journal of Clinical Virology
Volume 46, Supplement 4 , Pages S68-S72, December 2009

Article Tools

* Image Usage & Resolution